Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Clinical Pharmacology and Pharmacotherapy, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Drug Test Anal. 2020 Aug;12(8):1183-1195. doi: 10.1002/dta.2812. Epub 2020 Jun 5.
Colistin (polymyxin E) is a polycation antibiotic which is increasingly used (administered as colistin methanesulfonate, CMS) as a salvage therapy in critically ill patients with multidrug resistant Gram-negative infections. Even though colistin has been used for more than 50 years, its metabolic fate is poorly understood. One of the current challenges for studying the pharmacokinetics (PK) is the precise and accurate determination of colistin in in vitro and in vivo studies. In the present study, we developed and validated a series of sensitive and robust liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for analysing biological samples obtained from in vitro and in vivo disposition assays. After a zinc acetate-mediated precipitation, hydrophilic-lipophilic-balanced solid phase extraction (HLB-SPE) was used for the extraction of colistin. The compounds were retained on a hydrophilic interaction liquid chromatography (HILIC) column and were detected by MS/MS. CMS was quantified by determining the produced amount of colistin during acidic hydrolysis. The developed methods are sensitive with lower limits of quantification varying between 0.009 μg/mL and 0.071 μg/mL for colistin A, and 0.002 μg/mL to 0.013 μg/mL for colistin B. The intra- and inter-day precision and accuracy were within ±15%. Calibration curves of colistin were linear (0.063 μg/mL to 8.00 μg/mL) within clinically relevant concentration ranges. Zinc acetate-mediated precipitation and the use of a HILIC column were found to be essential. The developed methods are sensitive, accurate, precise, highly efficient and allow monitoring colistin and CMS in biological samples without the need for an internal standard.
黏菌素(多黏菌素 E)是一种多阳离子抗生素,作为多药耐药革兰氏阴性感染危重症患者的挽救疗法,其使用量(作为黏菌素甲磺酸盐,CMS)正在不断增加。尽管黏菌素已经使用了 50 多年,但人们对其代谢命运仍知之甚少。目前研究药代动力学(PK)的一个挑战是在体外和体内研究中准确、精确地测定黏菌素。在本研究中,我们开发并验证了一系列用于分析来自体外和体内处置研究的生物样品的灵敏而强大的液相色谱串联质谱(LC-MS/MS)方法。在醋酸锌介导的沉淀后,亲水-疏水平衡固相萃取(HLB-SPE)用于提取黏菌素。该化合物保留在亲水相互作用色谱(HILIC)柱上,并通过 MS/MS 检测。CMS 通过在酸性水解过程中确定产生的黏菌素量进行定量。所开发的方法具有较高的灵敏度,其定量下限在 0.009 μg/mL 至 0.071 μg/mL 之间(用于黏菌素 A),0.002 μg/mL 至 0.013 μg/mL 之间(用于黏菌素 B)。日内和日间精密度和准确度均在±15%范围内。黏菌素的校准曲线呈线性(0.063 μg/mL 至 8.00 μg/mL),处于临床相关浓度范围内。发现醋酸锌介导的沉淀和使用 HILIC 柱是必不可少的。所开发的方法灵敏、准确、精密、高效,无需内标即可监测生物样品中的黏菌素和 CMS。